Skip to main content
OpenTrials

Clinical trial condition

TDP-43 Proteinopathies

Explore clinical trials studying TDP-43 Proteinopathies. Study availability and eligibility vary by location and protocol.

870 public trials 211 recruiting studies
Refine in advanced search Browse all conditions

TDP-43 Proteinopathies trial results

Active, Not Recruiting

A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

NCT04747431

Conditions
Brain Diseases, C9orf72, Central Nervous System Diseases, +16 more
Locations
  • Michigan Alzheimer's Disease Center Ann Arbor, Michigan, United States
  • University of Pennsylvania Philadelphia, Pennsylvania, United States
  • Vanderbilt University Medical Center Nashville, Tennessee, United States
  • University of Texas at Houston Houston, Texas, United States
View Trial Details
Active, Not Recruiting

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

NCT05633459

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • Universitaire Ziekenhuizen Leuven (UZ Leuven) Leuven, Belgium
  • University of Calgary Calgary, Alberta, Canada
  • University of Alberta Edmonton, Alberta, Canada
  • Sunnybrook Health Science Centre Toronto, Ontario, Canada
View all 15 locations
View Trial Details
Active, Not Recruiting

Novel MRI Biomarkers for Monitoring Disease Progression in ALS

NCT03362658

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • University of Miami Miami, Florida, United States
  • University of Utah Salt Lake City, Utah, United States
  • University of Calgary / Heritage Medical Research Clinic Calgary, Alberta, Canada
  • University of Alberta Edmonton, Alberta, Canada
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

NCT05279755

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Worldwide Clinical Trials Early Phase Services San Antonio, Texas, United States
  • The Neuro - Montréal Neurological Institute-Hospital Montreal, Quebec, Canada
  • University Medical Center Utrecht Utrecht, Netherlands
View Trial Details
Active, Not Recruiting

A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT06441682

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • UZ Leuven Leuven, Belgium
  • Kaye Edmonton Clinic Edmonton, Canada
  • Montreal Neurological Institute and Hospital Montreal, Canada
  • Aarhus Universitets Hospital Aarhus, Denmark
View Trial Details
Active, Not Recruiting

ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

NCT05928416

Conditions
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic lateral sclerosis 1, +10 more
Locations
  • CHU Strasbourg Strasbourg, Alsace, France
  • CHU Nantes Saint-Herblain, Loire-Atlantique, France
  • C.H.U. de Saint-Étienne Saint-Étienne-de-Montluc, Pays de la Loire Region, France
  • Hospices Civils de Lyon Bron, Rhône, France
View all 19 locations
View Trial Details
Active, Not Recruiting

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

NCT04057898

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • University of California Orange, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Augusta University Augusta, Georgia, United States
  • Indiana University IU Health Neuroscience Center Indianapolis, Indiana, United States
View all 16 locations
View Trial Details

Related conditions